#biotechs #IPO
Google, Initial public offering, Biotechnology, Therapy, Medicine, Venture capital

With $588M IPO, Sana leads wave of new biotechs going public

On Feb 4, 2021
@BentheFidler shared
With $588M #IPO, Sana leads wave of new #biotechs going public $SANA https://t.co/qo7HXoVY0x Some stats: -3rd largest IPO since 2018 -biggest cell/gene therapy IPO -biggest preclinical IPO https://t.co/3oevWN9pls
Open

Nine other drug developers are set to price initial public offerings this week, extending a record run of financing activity from last year. Sana's is one of the largest in history. 

www.biopharmadive.com
On Feb 4, 2021
@BentheFidler shared
With $588M #IPO, Sana leads wave of new #biotechs going public $SANA https://t.co/qo7HXoVY0x Some stats: -3rd largest IPO since 2018 -biggest cell/gene therapy IPO -biggest preclinical IPO https://t.co/3oevWN9pls
Open

With $588M IPO, Sana leads wave of new biotechs going public

With $588M IPO, Sana leads wave of new biotechs going public

Nine other drug developers are set to price initial public offerings this week, extending a record run of financing activity from last year. Sana's is one of the largest in history. 

Biotech IPOs near last year's pace, despite COVID-19 pandemic

Biotech IPOs near last year's pace, despite COVID-19 pandemic

A successful IPO from Pliant Therapeutics is the first of five potential offerings by biotechs this week, suggesting activity is picking up following earlier coronavirus-related disruption.

Sana Biotechnology files to go public, looks to cure disease by modifying genes in the body

Sana Biotechnology files to go public, looks to cure disease by modifying genes in the body

Less than three years after it was founded and with no revenue on the books, Sana Biotechnology filed to go public on Wednesday in what would be the latest Seattle biotech company to test ...

3 trends in biotech to watch in 2019

3 trends in biotech to watch in 2019

Here are three trends to watch in biotech in 2019, a year that that looks to be laden with opportunities and stumbling blocks for the drug industry.

Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More

Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More

The coronavirus pandemic has shaken the global economy, but three life sciences venture capital firms this week announced new funds totaling nearly $3

FDA to ramp up cell and gene therapy activity as tidal wave of new products approaches

FDA to ramp up cell and gene therapy activity as tidal wave of new products approaches

In a statement, Commissioner Scott Gottlieb said the agency anticipates more than 200 cell and gene therapy INDs per year by 2020, and 10-20 approvals annually by 2025.

The CipherBio List of Top Life Science Investors in 2019 and 2020

The CipherBio List of Top Life Science Investors in 2019 and 2020

Meet the life science investors that backed some of the top performing biotech companies in 2019 and 2020.

The Future of Cell and Gene Therapy Manufacturing Just Got Brighter

The Future of Cell and Gene Therapy Manufacturing Just Got Brighter

Advances in cell and gene therapies (CGT) offer the potential to transform medicine. They create an inflection point in the ability to treat and potentially cure many intractable illnesses. ...

Why and How to Prepare for a Successful Biotech IPO

Why and How to Prepare for a Successful Biotech IPO

Any biotech company that has reached a certain size and is in need of investment will have to consider the critical question: is it time to go public? Navigating the stock market can be ...

From Launch To IPO In 13 Months: Gossamer Bio’s CEO Says She’s Running The Company Of Her Dreams

From Launch To IPO In 13 Months: Gossamer Bio’s CEO Says She’s Running The Company Of Her Dreams

Immunology-focused biotech startup Gossamer Bio has its market debut, with a lead drug candidate targeting moderate-to-severe asthma.

Second attempt: ADC Therapeutics starts IPO process

Second attempt: ADC Therapeutics starts IPO process

Last October ADC cancelled its IPO due to “adverse market conditions”. ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company pioneering the development and ...

Biopharma industry on pace to smash record for financings

Biopharma industry on pace to smash record for financings

Amid a world that has been brought to its knees by the COVID-19 pandemic, the biopharma industry has learned how to quickly adapt under these extreme circumstances. Not only has it rapidly ...

Top Ten Events in Advanced Therapies 2019

Top Ten Events in Advanced Therapies 2019

“We want to become the first, not the last therapeutic option.”   A remark that reverberated around the plenary hall at last week’s Phacilitate Leaders World in Miami. Bob Preti opened the ...

Reflections On An Unprecedented Decade In The Cell And Gene Therapy Field

Reflections On An Unprecedented Decade In The Cell And Gene Therapy Field

Having launched near the beginning of the last decade, Toronto-based CCRM has had a ringside seat to the noteworthy advances in our industry —...

Montreal biotech Repare poised to join US$1-billion club as stock set to debut on Nasdaq Friday

Montreal biotech Repare poised to join US$1-billion club as stock set to debut on Nasdaq Friday

The cancer drug developer said it would sell 11 million shares at US$20 apiece